This combination is indicated for the symptomatic relief of upper respiratory tract conditions associated with productive cough, where benefit is obtained from a nasal decongestant, an H1 histamine receptor antagonist, and an expectorant.

Pseudoephedrine acts as a nasal decongestant and mild bronchodilator, providing relief from nasal congestion. It is an α- and β-adrenergic receptor agonist. It produces vasoconstriction by stimulating α-adrenergic receptors in the respiratory mucosa, thereby reducing congestion. It also stimulates β-adrenergic receptors, leading to bronchodilation, increased heart rate, and increased cardiac contractility.

Additionally, pseudoephedrine exerts an indirect effect by releasing norepinephrine from presynaptic storage sites. The released norepinephrine activates postsynaptic adrenergic receptors, contributing to its therapeutic effects.

Guaifenesin acts as an expectorant by reducing the viscosity of thick bronchial secretions. It increases respiratory tract hydration, thereby enhancing mucus volume and reducing sputum thickness, making it easier to expectorate.

Triprolidine is an H1 antihistamine that provides symptomatic relief in allergic conditions such as rhinitis, conjunctivitis, and urticaria by blocking histamine receptors.

Adult and Children over 12 years: 10 ml (2 teaspoonful) three times a day.

Children 6-12 years: 5 ml (1 teaspoonful) three times a day.

Children 2-5 years: 2.5 ml (1/2 teaspoonful) three times a day.

A physician’s advice is preferred before administering this preparation to children aged less than 2 years.

Concomitant use of pseudoephedrine, guaifenesin, and triprolidine with other sympathomimetic agents such as nasal decongestants, tricyclic antidepressants, appetite suppressants, and amphetamine-like stimulants, or with monoamine oxidase inhibitors (MAOIs), may occasionally lead to increased blood pressure due to enhanced sympathomimetic effects. Due to the presence of pseudoephedrine, this combination may partially reduce the antihypertensive effect of drugs that act on sympathetic pathways, including guanethidine, methyldopa, and alpha-adrenergic blocking agents.

Contraindicated in patients with known hypersensitivity to any component, cardiovascular disease including hypertension, lower respiratory tract conditions such as asthma, and in patients receiving monoamine oxidase inhibitor (MAOI) therapy.

Central nervous system depression or stimulation, drowsiness (most common), sleep disturbances, hallucinations (rare), skin rash with or without irritation, tachycardia, and dryness of mouth, nose, and throat have been reported occasionally.

Although pseudoephedrine, guaifenesin, and triprolidine have been widely used without clear evidence of harm, there are no adequate controlled studies in pregnancy. Therefore, use should be based on a careful risk-benefit assessment for the mother and fetus.

May cause drowsiness; patients should avoid driving or operating machinery if affected. Alcohol and CNS depressants should be avoided. Use with caution in mild to moderate hypertension and in patients with diabetes, hyperthyroidism, cardiovascular disease, raised intraocular pressure, prostatic enlargement, and severe renal or hepatic impairment. Not recommended for chronic or persistent cough associated with smoking, asthma, or emphysema unless advised by a physician.

Symptoms may include drowsiness, irritability, restlessness, dizziness, gastrointestinal discomfort, respiratory depression, tremor, convulsions, tachycardia, and hypertension. Management includes supportive care, airway maintenance, seizure control, and gastric lavage if necessary.

Combined cough expectorants

Store below 25°C. Protect from light. Do not refrigerate.